Clinical Pharmacy The Andexxa Paradox Andexxa withdrawn after ANNEXA-I showed higher stroke risk; clinicians return to 4F-PCC for DOAC reversal while new agents emerge.
Clinical Pharmacy 2026 GOLD Report Updates Discover what’s new in the 2026 GOLD COPD Report including earlier detection, new risk definitions, treatment updates, and emerging tech shaping patient care.
Clinical Pharmacy Potassium and Hypertension Increasing potassium intake lowers blood pressure, reduces stroke risk, and may decrease antihypertensive medication needs.
Clinical Pharmacy Updates in the 2025 ACC/AHA Hypertension Guidelines The 2025 ACC/AHA hypertension guidelines emphasize earlier detection, lifestyle changes, new PREVENTâ„¢ risk tool, and team-based care.